Gotowa bibliografia na temat „Cancers du côlon métastatiques”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Cancers du côlon métastatiques”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Cancers du côlon métastatiques"
Diallo, AC, A. Ndong, JIAT Thiam, MB Ba, PS Dieng, RO Somé, D. Diouf, MM Dieng, S. Ka i A. Dem. "C44: Cancers coliques en occlusion : Résection ou stomie ?" African Journal of Oncology 2, nr 1 Supplement (1.03.2022): S19. http://dx.doi.org/10.54266/ajo.2.1s.c44.sweaiwgufg.
Pełny tekst źródłaWagner, Anna Dorothea, Khalil Zaman, Solange Peters i Michael Montemurro. "Traitements [b]antiangiogéniques[/b] des cancers métastatiques du côlon et du rectum, du sein et du poumon : bénéfices et risques". Revue Médicale Suisse 6, nr 250 (2010): 1070–73. http://dx.doi.org/10.53738/revmed.2010.6.250.1070.
Pełny tekst źródłaAparicio, T., P. Wind i G. Des Guetz. "Prise en charge des cancers du côlon non métastatique chez les patients âgés". Côlon & Rectum 7, nr 3 (1.07.2013): 150–55. http://dx.doi.org/10.1007/s11725-013-0462-x.
Pełny tekst źródłaAmoura, M. O., K. Hail, L. Khelifi, A. Hablal, H. Chatter, A. Benmechta i N. Sid Idris. "La chimiothérapie néo-adjuvante à base de FOLFOX dans la prise en charge des cancers du côlon non métastatiques : un nouveau concept prometteur ?" Journal de Chirurgie Viscérale 159, nr 4 (wrzesień 2022): S75. http://dx.doi.org/10.1016/j.jchirv.2022.07.024.
Pełny tekst źródłaLapeyre-Prost, A., i J. Taieb. "Cancer du côlon non métastatique : désescalade thérapeutique". Côlon & Rectum 12, nr 3 (sierpień 2018): 161–69. http://dx.doi.org/10.3166/cer-2018-0025.
Pełny tekst źródłaKaroui, M., C. Debove i J. H. Lefevre. "La chimiothérapie néoadjuvante dans le cancer du côlon non métastatique". Côlon & Rectum 12, nr 1 (marzec 2018): 42–47. http://dx.doi.org/10.3166/cer-2018-0003.
Pełny tekst źródłaRodier, J. M., i F. Mefti. "Cancers du sein métastatiques". Oncologie 7, S4 (sierpień 2005): ns25—ns26. http://dx.doi.org/10.1007/s10269-005-0234-9.
Pełny tekst źródłaMaggiori, L., i Y. Panis. "Chirurgie du cancer du côlon non métastatique, critères de qualité, avancées récentes". Côlon & Rectum 7, nr 3 (22.06.2013): 161–67. http://dx.doi.org/10.1007/s11725-013-0463-9.
Pełny tekst źródłaBrachet, D., E. Lermite, S. Mucci-Hennekinne i J. P. Arnaud. "Cancers du côlon en occlusion". EMC - Techniques chirurgicales - Appareil digestif 4, nr 2 (styczeń 2009): 1–8. http://dx.doi.org/10.1016/s0246-0424(09)51060-6.
Pełny tekst źródłaGrodos, J., i J. Haot. "Les cancers synchrones du côlon". Acta Endoscopica 17, nr 1 (styczeń 1987): 11–17. http://dx.doi.org/10.1007/bf02965228.
Pełny tekst źródłaRozprawy doktorskie na temat "Cancers du côlon métastatiques"
Barrier, Alain. "Prédiction du pronostic des cancers coliques non métastatiques par les profils d'expression génique". Paris 6, 2006. http://www.theses.fr/2006PA066440.
Pełny tekst źródłaMeunier, Katy. "Influence du statut MSI et des principales altérations génétiques des cancers coliques sur l’évolution tumorale métastatique naturelle et après chirurgie". Paris 6, 2013. http://www.theses.fr/2013PA066332.
Pełny tekst źródłaThe first aim was to investigate the influence of mutations characteristics of tumours displaying microsatellite instability (MSI), due to mismatch repair system (MMR) deficiency, in tumour invasion and metastatic potential. For this purpose, we set up a model of orthotopic xenograft in NOD/SCID mice using the human MSI colon cancer cell line HCT116, deficient in MLH1, a key MMR actor and its isogenic cell line obtained by transfecting a wild type MLH1 cDNA expression vector. Subcutaneous tumours were first established in mice; then, tumours were grafted onto the caecum and either left in situ to evaluate the natural evolution, or resected to assess clinical outcome after surgery. Our observations show that the expression of MLH1 improves clinical outcome of mice who underwent a curative surgical resection or when tumours were left in situ. The second objective was to compare the molecular characteristics of colon cancer with liver metastases and/or peritoneal carcinomatosis in a prospective multicentre study. Genome regions with copy number variations were identified by comparing DNA isolated from normal tissues and the different tumour sites using pan-genomic "HumanCNV370" chips. The level of genomic alterations in primary tumours is not indicative of evolution, and carcinomatosis as metastases may differ from each other and from the primary tumour. The intra-individual tumour heterogeneity has important consequences in clinics. Identifying a molecular signature in the primary tumour able to predict evolution, and defining the molecular characteristics of metastasis, should help clinicians to improve the therapeutic management of patients with colon cancer in the future
Maamer, Azzabi Aida. "Mécanismes moléculaires de l'acquisition d'une sensibilité à l'apoptose induite par l'ABT-737 et d'une résistance à l'anoïkis de cellules coliques métastatiques". Phd thesis, Université Paris Sud - Paris XI, 2013. http://tel.archives-ouvertes.fr/tel-00966853.
Pełny tekst źródłaDouard, Richard. "Potentiel métastatique des cellules circulantes dans le cancer colorectal". Paris 12, 2006. https://athena.u-pec.fr/primo-explore/search?query=any,exact,990002457730204611&vid=upec.
Pełny tekst źródłaCirculating cancer cells have been thought to have a great part in the development of distant metastasis in epithelial tumours. The aim of this work was to assess their prognostic value in colorectal cancer using several detection techniques. RT-PCR CGM2 detection in the preoperative peripheral blood is not correlated with either survival or recurrence-free survival. RT-PCR detection using two specific markers of the colon tissue (ACE/CGM2) either allows to improve detection specificity or to label several subpopulations of circulating cells. The interest of quantitative RT-PCR techniques was assessed for CK20. The additional dissemination related to colorectal cancer excision has been assessed to be about 10% using a qualitative multiplex (ACE/CGM2) RT-PCR technique. These results were compared to those obtained with cancer-specific markers (MAGE). The prognostic value of circulating malignant cells has been compared in colorectal and prostate cancers. The potential interest of circulating cells in peritoneal cavity has also been studied. An isolation technique has allowed to retrieve more than 98% of blood nucleated cells and thus become the first step to the physical study of the genotype and metastatic potential of circulating cells
Limacher, Jean-Marc. "Biomodulation du 5-fluorouracile dans les cancers colo-rectaux métastatiques". Université Louis Pasteur (Strasbourg) (1971-2008), 1992. http://www.theses.fr/1992STR1M192.
Pełny tekst źródłaLemaire, Valérie. "Adénocarcinome du côlon : mise en évidence par RT-PCR de la dissémination hématogène de cellules coliques au stade métastatique". Paris 5, 1995. http://www.theses.fr/1995PA05P272.
Pełny tekst źródłaBenzekry, Sébastien. "Modélisation, analyse mathématique de thérapies anti-cancéreuses pour les cancers métastatiques". Thesis, Aix-Marseille 1, 2011. http://www.theses.fr/2011AIX10094/document.
Pełny tekst źródłaWe introduce a mathematical model for the evolution of a cancer disease at the organism scale, taking into account for the metastases and their sizes as well as action of several therapies such as primary tumor surgery, chemotherapy and anti-angiogenic therapy. The mathematical problem is a renewal equation with bi-dimensional structuring variable. Mathematical analysis and functional analysis of an underlying Sobolev space are performed. Existence, uniqueness, regularity and asymptotic behavior of the solutions are proven in the autonomous case. A lagrangian numerical scheme is introduced and analyzed. Convergence of this scheme proves existence in the non-autonomous case. The effect of concentration of the boundary data into a Dirac mass is also investigated.Possible applications of the model are numerically illustrated for clinical issues such as the failure of anti-angiogenic monotherapies, scheduling of combined cytotoxic and anti-angiogenic therapies and metronomic chemotherapies. In order to give mathematical answers to these clinical problems an optimal control problem is formulated, analyzed and simulated
Montemagno, Christopher. "Développement de radiotraceurs pour l'imagerie phénotypique des cancers du sein métastatiques". Thesis, Université Grenoble Alpes (ComUE), 2018. http://www.theses.fr/2018GREAS039/document.
Pełny tekst źródłaBreast cancer is the leading cause of cancer among women. At the time of diagnosis, 30 % of patients have developed a metastatic disease either with regional lymph node colonization or distant organs colonization. Metastatic breast cancers are treated by chemotherapy or targeted therapy, according to histological results of primary site. However, 20 to 45 % of metastases have a different phenotype from the primary tumor. Getting access to metastases phenotype would therefore allow treating patients more accurately, in accordance with molecular characteristics of these lesions. Because metastases are not always accessible to biopsy, the use of molecular imaging could be of great interest. Nuclear medicine is the only molecular imaging technic available in clinical practice. The objective of this thesis was to perform the phenotypic imaging of metastatic breast cancer by targeting mesothelin and VCAM-1. The first part of this work was dedicated to the preclinical evaluation of mesothelin-targeting nanobodies. Mesothelin is a GPI-anchored membran protein. While its expression is restricted to a mesothelial cells in normal conditions, mesothelin is overexpressed in several cancers, including breast cancer. Several mesothelin-targeting therapies are currently ongoing clinical transfer. Identifying mesothelin-expressing metastases would allow to select patients who could benefit from those therapies. During this thesis, the nanobody-derived radiotracer 99mTc-A1 has been fully validated for the imaging of mesothelin expressing tumors. The second part of this work was dedicated to the nuclear imaging of VCAM-1 expressing breast cancer lesions. VCAM-1 is a membrane-associated protein involved in the metastatic spread of breast tumor cells. An imaging agent targeting at VCAM-1 could be a suitable tool to evaluate the role of VCAM-1 as a marker of tumor aggressiveness. In the present study, the nanobody 99mTc-cAbVCAM1-5 has been validated for the imaging of VCAM-1 expression in breast cancer
Terret, Catherine. "Optimisation de la chimiothérapie du cancer colorectal métastatique par 5-FU et CPT-11 : données de pharmacocinétique, de chimiosensibilité". Toulouse 3, 2000. http://www.theses.fr/2000TOU30166.
Pełny tekst źródłaTournigand, Christophe. "Stratégie thérapeutique des cancers colorectaux métastatiques : du 5-fluorouracile aux thérapies ciblées". Paris 6, 2005. http://www.theses.fr/2005PA066253.
Pełny tekst źródłaKsiążki na temat "Cancers du côlon métastatiques"
B, Dubois J., Joyeux Henri i Serrou B, red. Cancers du côlon-rectum, de l'ovaire, du foie: Bases fondamentales, nutrition et associations thérapeutiques : Montpellier, 28-30 avril 1986. Paris: Éditions de l'Institut national de la santé et de la recheche médicale, 1987.
Znajdź pełny tekst źródłaCzęści książek na temat "Cancers du côlon métastatiques"
Fumoleau, P. "RBU et cancers du sein métastatiques". W Cancer du sein en situation métastatique, 463. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_41.
Pełny tekst źródłaVillanueva, C., F. Bazan, L. Chaigneau, L. Cals, V. Sylvestre i X. Pivot. "Traitements systémiques des cancers du sein métastatiques". W Thérapeutique du cancer, 185–96. Paris: Springer Paris, 2011. http://dx.doi.org/10.1007/978-2-8178-0021-9_13.
Pełny tekst źródłaBourgier, C., W. Khodari i D. Azria. "Irradiation locorégionale des cancers du sein d’emblée métastatiques". W Cancer du sein en situation métastatique, 129–34. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_14.
Pełny tekst źródłaCoudert, B., S. Guiu, H. Tixier, F. Mayer i P. Fumoleau. "Stratégies thérapeutiques des cancers métastatiques RH+, HER2+ : trastuzumab, chimiothérapie, hormonothérapie". W Cancer du sein en situation métastatique, 207–21. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_21.
Pełny tekst źródłaDucreux, M., V. Boige, D. Malka i P. Burtin. "Le traitement médical des cancers colorectaux métastatiques en 2009: quels traitements pour quels patients?" W Post’U FMC-HGE, 56–64. Paris: Springer Paris, 2009. http://dx.doi.org/10.1007/978-2-287-99247-6_7.
Pełny tekst źródłaGuiu, S., B. Coudert i P. Fumoleau. "Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs". W Cancer du sein, 499–528. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_33.
Pełny tekst źródłaRay-Coquard, I., J. P. Guastalla, T. Bachelot, O. Tredan, I. Labidi Gady i A. Duret. "Que décider après l’apparition d’un échappement aux anti-angiogéniques actuels prescrits aux cancers du sein métastatiques ?" W Cancer du sein en situation métastatique, 459–62. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_40.
Pełny tekst źródłaDebled, M., i L. Mauriac. "Stratégies thérapeutiques des cancers du sein métastatiques : RH+ HER2−. Hormonothérapies, chimiothérapies (monochimiothérapies séquentielles ou polychimiothérapies concomitantes ?), antiangiogéniques". W Cancer du sein en situation métastatique, 181–205. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_20.
Pełny tekst źródłaNabholtz, J. M. "Analyse des recommandations du National Comprehensive Cancer Network portant sur les cancers du sein métastatiques V.1.2009". W Cancer du sein en situation métastatique, 355–61. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_36.
Pełny tekst źródłaVieillard, M. H. "Les bisphosphonates pour les cancers métastatiques du sein : utiles ou futiles ? Pour quelles localisations et avec quelle surveillance ?" W Cancer du sein en situation métastatique, 295–305. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_29.
Pełny tekst źródła